OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Baskin on Mitigating Patient Concerns During the COVID-19 Pandemic in Prostate Cancer

November 12th 2020

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

Dr. Vesole on the Mechanism of Action of Belantamab Mafodotin in Multiple Myeloma

November 12th 2020

David H. Vesole, MD, PhD, discusses the mechanism of action of belantamab mafodotin-blmf in multiple myeloma.

Dr. Saba Discusses Ongoing Trials in Head and Neck Cancer

November 12th 2020

Nabil F. Saba, MD, FACP, discusses ongoing clinical trials in head and neck cancer.

Dr. Bagegni on the Safety Profile of T-DM1 in Early-Stage HER2+ Breast Cancer

November 12th 2020

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.

Dr. Brody on the Challenges of Antigen Escape in MCL

November 12th 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

Dr. Zalcberg on the Role of Ripretinib in Advanced GIST

November 10th 2020

John Zalcberg, PhD, OAM, discusses the role of Gastrointestinal Cancer in advanced gastrointestinal stromal tumor.

Dr. Cavnar on the Importance of Multidisciplinary Care in CRC

November 10th 2020

Michael J. Cavnar, MD, discusses the importance of multidisciplinary care in colorectal cancer.

Dr. Costello on Treatment Selection Considerations in Multiple Myeloma

November 10th 2020

Caitlin Costello, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Ruan on the Incidence of MCL

November 10th 2020

Jia Ruan, MD, PhD, discusses the incidence of mantle cell lymphoma.

Dr. Danilov on the Role of Disease Biology in Up-front Treatment Selection in CLL

November 10th 2020

Alexey V. Danilov, MD, PhD, discusses the role of disease biology in up-front treatment selection in chronic lymphocytic leukemia.

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

November 10th 2020

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Dr. Ahn on the Role of Checkpoint Inhibitors in NTRK Fusion+ MSI-H CRC

November 10th 2020

Daniel H. Ahn, DO, discusses the role of checkpoint inhibitor therapy in patients with microsatellite instability–high colorectal cancer who harbor an NTRK fusion.

Dr. Benson on the Complexity of Up-front Treatment in HCC

November 10th 2020

Al B. Benson, MD, discusses the complexity of up-front treatment in hepatocellular carcinoma.

Dr. Lunning on Initial Treatment Considerations in CLL

November 10th 2020

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Dr. Beltran on the Significance of Genomic Sequencing in Prostate Cancer

November 9th 2020

Himisha Beltran, MD, discusses the significance of genomic sequencing in prostate cancer.

Dr. Skarbnik on the Approval of Brexucabtagene Autoleucel in MCL

November 9th 2020

Alan P. Z. Skarbnik, MD, discusses the approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer

November 9th 2020

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Dr. Rohs on the Importance of Genetic Testing in NSCLC

November 7th 2020

Nicholas C. Rohs, MD, discusses the importance of genetic testing in non–small cell lung cancer.

Dr. Rizk on the Evolution of Surgery in Lung Cancer

November 7th 2020

Nabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.

Dr. McGregor the Potential Utility of Cabozantinib/Nivolumab in Advanced RCC

November 7th 2020

Bradley McGregor, MD, discusses the potential utility of the combination of cabozantinib and nivolumab in advanced renal cell carcinoma (RCC).